Estradiol vaginal - TherapeuticsMD

Drug Profile

Estradiol vaginal - TherapeuticsMD

Alternative Names: Estradiol VagiCap™; TX- 12-004-HR; TX-004HR; VagiCap; Yuvvexy

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TherapeuticsMD
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Hormones; Pregnenediones; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Atrophic vaginitis

Most Recent Events

  • 19 Dec 2017 FDA assigns PDUFA action date of 29/05/2018 for Estradiol vaginal for Atrophic vaginitis
  • 19 Dec 2017 US FDA accepts NDA resubmission for estradiol vaginal for Atrophic vaginitis for review
  • 29 Nov 2017 TherapeuticsMD re-submits NDA to the US FDA for estradiol vaginal for Atrophic vaginitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top